BioDrain Announces Additional Trial Installations and Sales of BioDrain STREAMWAY® Systems Across the U.S.
BioDrain Announces Additional Trial Installations and Sales of BioDrain STREAMWAY® Systems Across the U.S.MINNEAPOLIS, March 5, 2013 /PRNewswire/ -- BioDrain Medical, Inc., (OTCQB: BIOR) ("BioDrain"), producer of the FDA approved STREAMWAY® System for automated, direct-to-drain surgical fluid disposal that reduces the risk of exposure to hazardous waste, announced today that it has completed additional trial installations and sales over the last sixty days of its STREAMWAY® Systems into hospitals and surgical centers in various states including New York, Michigan, Minnesota and Pennsylvania. These additional installations and sales included both new and repeat customers.
Prior trial installations of BioDrain's STREAMWAY® System have resulted in a 100% success rate in conversions from a trial installation to a subsequent sale of the system. In addition, BioDrain has upcoming meetings scheduled with potential distributors in Europe, Canada and Asia, in an effort to commence the global expansion of its STREAMWAY® System.
"The lack of availability of fluid management solutions has created a demand for an FDA approved product," commented Josh Kornberg, Chief Executive Officer of BioDrain Medical. "We believe our FDA approved product provides a technologically advanced fluid management solution that is superior to the current manual solution which relies on manual disposal systems and canisters. We are extremely pleased with these initial installations and look forward to expanding our presence globally in an effort to increase our market share worldwide."
BioDrain Medical, Inc. has a fully automated, patented, FDA cleared, surgical fluid disposal system that virtually eliminates operating room workers' exposure to blood, irrigation fluid and other potentially infectious fluids found in the surgical environment. Today's manual surgical fluid handling methods of hand-carrying filled surgical fluid canisters and emptying these canisters is an exposure risk and an antiquated approach to the handling of surgical fluid waste. BioDrain's STREAMWAY® System fully automates the collection, measurement and disposal of surgical fluids and is designed to result in: 1) reducing overhead costs to hospitals and surgical centers, 2) improving Occupational State and Health Association (OSHA) and other regulatory compliance agencies' safety concerns, and 3) streamlining the efficiency of the operating room (and thereby making surgeries more profitable).
BioDrain's STREAMWAY® System is eco-friendly as it contributes to cleaning up the environment. Currently, approximately 50 million bloody, potentially disease infected canisters go to landfills annually in the United States. These tainted canisters can remain in landfills for years to come. With the installation of BioDrain's STREAMWAY® System, the number of canisters can be significantly reduced which assists in making the operating room and our environment safer, cleaner, and better. BioDrain products are currently being represented by independent professional sales representatives that cater to the needs of hospitals and ambulatory surgical centers across the country. For additional information, please visit: www.biodrainmedical.com.
Certain of the matters discussed in this announcement contain forward-looking statements that involve material risks to and uncertainties in the company's business that may cause actual results to differ materially from those anticipated by the statements made herein. Such risks and uncertainties include, among other things, our ability to establish and maintain the proprietary nature of our technology through the patent process, as well as our ability to possibly license from others patents and patent applications necessary to develop products; the availability of financing; the company's ability to implement its long range business plan for various applications of its technology; the company's ability to enter into agreements with any necessary marketing and/or distribution partners; the impact of competition, the obtaining and maintenance of any necessary regulatory clearances applicable to applications of the company's technology; and management of growth and other risks and uncertainties that may be detailed from time to time in the company's reports filed with the Securities and Exchange Commission. This is not a solicitation to buy or sell securities and does not purport to be an analysis of the company's financial position. See the Company's most recent Quarterly Report on Form 10-Q and subsequent 8-K filings.
Public Relations Contact: Samantha Wolf KCSA Strategic Communications 212-896-1220 email@example.com